Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC)

zu Verbundenen Objekten

Standort
Deutsche Nationalbibliothek Frankfurt am Main
ISSN
1776-260X
Umfang
Online-Ressource
Sprache
Englisch
Anmerkungen
online resource.

Erschienen in
Exploring the Impact of Treatment Switching on Overall Survival from the PROfound Study in Homologous Recombination Repair (HRR)-Mutated Metastatic Castration-Resistant Prostate Cancer (mCRPC) ; volume:16 ; number:5 ; day:3 ; month:9 ; year:2021 ; pages:613-623 ; date:9.2021
Targeted oncology ; 16, Heft 5 (3.9.2021), 613-623, 9.2021

Klassifikation
Medizin, Gesundheit

Urheber
Evans, Rachel
Hawkins, Neil
Dequen-O’Byrne, Pascale
McCrea, Charles
Muston, Dominic
Gresty, Christopher
Ghate, Sameer R.
Fan, Lin
Hettle, Robert
Abrams, Keith R.
Bono, Johann de
Hussain, Maha
Agarwal, Neeraj
Beteiligte Personen und Organisationen
SpringerLink (Online service)

DOI
10.1007/s11523-021-00837-y
URN
urn:nbn:de:101:1-2021121907174022632146
Rechteinformation
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
Letzte Aktualisierung
15.08.2025, 07:31 MESZ

Datenpartner

Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Original beim Datenpartner anzeigen

Beteiligte

  • Evans, Rachel
  • Hawkins, Neil
  • Dequen-O’Byrne, Pascale
  • McCrea, Charles
  • Muston, Dominic
  • Gresty, Christopher
  • Ghate, Sameer R.
  • Fan, Lin
  • Hettle, Robert
  • Abrams, Keith R.
  • Bono, Johann de
  • Hussain, Maha
  • Agarwal, Neeraj
  • SpringerLink (Online service)

Ähnliche Objekte (12)

Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina

Budget Impact Analysis of Olaparib for the Management of Patients with Homologous Recombination Repair (HRR)-Mutated Castration-Resistant Metastatic Prostate Cancer in Argentina

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

Targeting molecular resistance in castration-resistant prostate cancer

Targeting molecular resistance in castration-resistant prostate cancer

Evolving Personalized Therapy for Castration-Resistant Prostate Cancer

Evolving Personalized Therapy for Castration-Resistant Prostate Cancer

Osteoclasts directly influence castration-resistant prostate cancer cells

Osteoclasts directly influence castration-resistant prostate cancer cells

Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

Publisher Correction: First-line talazoparib with enzalutamide in HRR-deficient metastatic castration-resistant prostate cancer: the phase 3 TALAPRO-2 trial

Effect of simvastatin on castration-resistant prostate cancer cells

Effect of simvastatin on castration-resistant prostate cancer cells

Ureter metastatic castration-resistant prostate cancer: a case report

Ureter metastatic castration-resistant prostate cancer: a case report

Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends

Nonmetastatic Castration-Resistant Prostate Cancer: Current Challenges and Trends

Physician preferences for non-metastatic castration-resistant prostate cancer treatment

Physician preferences for non-metastatic castration-resistant prostate cancer treatment

Ailanthone: a new potential drug for castration-resistant prostate cancer

Ailanthone: a new potential drug for castration-resistant prostate cancer

Chromogranin A: a useful biomarker in castration-resistant prostate cancer

Chromogranin A: a useful biomarker in castration-resistant prostate cancer

Verbundene Objekte